2020
Comparative Effectiveness of Generic vs Brand-Name Levothyroxine in Achieving Normal Thyrotropin Levels
Brito JP, Ross JS, Sangaralingham L, Dutcher SK, Graham DJ, Wang Z, Wu Y, Yao X, Smallridge RC, Bernet V, Shah ND, Lipska KJ. Comparative Effectiveness of Generic vs Brand-Name Levothyroxine in Achieving Normal Thyrotropin Levels. JAMA Network Open 2020, 3: e2017645. PMID: 32997127, PMCID: PMC7527873, DOI: 10.1001/jamanetworkopen.2020.17645.Peer-Reviewed Original ResearchConceptsNormal thyrotropin levelsPropensity score-matched patientsThyrotropin levelsLevothyroxine prescriptionsThyrotropin valuesProportion of patientsAdministrative claims databaseMonths of initiationMIU/LMild thyroid dysfunctionLongitudinal cohort studyMedicare Advantage enrolleesNormal thyrotropin valuesEligible patientsInitial therapyLevothyroxine formulationsCohort studyThyroid dysfunctionClaims databaseGeneric levothyroxineLevothyroxineMAIN OUTCOMENormal rangePatientsNormal vs
2018
Speed of Adoption of Immune Checkpoint Inhibitors of Programmed Cell Death 1 Protein and Comparison of Patient Ages in Clinical Practice vs Pivotal Clinical Trials
O’Connor J, Fessele KL, Steiner J, Seidl-Rathkopf K, Carson KR, Nussbaum NC, Yin ES, Adelson KB, Presley CJ, Chiang AC, Ross JS, Abernethy AP, Gross CP. Speed of Adoption of Immune Checkpoint Inhibitors of Programmed Cell Death 1 Protein and Comparison of Patient Ages in Clinical Practice vs Pivotal Clinical Trials. JAMA Oncology 2018, 4: e180798-e180798. PMID: 29800974, PMCID: PMC6143052, DOI: 10.1001/jamaoncol.2018.0798.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntibodies, Monoclonal, HumanizedCarcinoma, Non-Small-Cell LungCarcinoma, Renal CellClinical Trials as TopicFemaleFollow-Up StudiesHumansKidney NeoplasmsLung NeoplasmsMaleMiddle AgedNivolumabPractice Patterns, Physicians'PrognosisProgrammed Cell Death 1 ReceptorRetrospective StudiesConceptsNon-small cell lung cancerPivotal clinical trialsRenal cell carcinomaCell death 1 proteinEligible patientsImmune checkpoint inhibitorsDeath 1 proteinClinical trialsClinical practiceFDA approvalAgent treatmentCheckpoint inhibitorsAnti-PD-1 agentsFlatiron Health networkRetrospective cohort studyAge of patientsCell lung cancerClinical trial participantsCohort studyPatient ageYounger patientsMore patientsSuch patientsTrial evidenceCell carcinoma
2016
Intensive Treatment and Severe Hypoglycemia Among Adults With Type 2 Diabetes
McCoy RG, Lipska KJ, Yao X, Ross JS, Montori VM, Shah ND. Intensive Treatment and Severe Hypoglycemia Among Adults With Type 2 Diabetes. JAMA Internal Medicine 2016, 176: 969-78. PMID: 27273792, PMCID: PMC5380118, DOI: 10.1001/jamainternmed.2016.2275.Peer-Reviewed Original ResearchConceptsType 2 diabetesHigh clinical complexityRisk-adjusted probabilitySevere hypoglycemiaIntensive treatmentClinical complexityStandard treatmentIntensive glucose-lowering treatmentEnd-stage renal diseasePatient clinical complexityGlucose-lowering medicationsGlucose-lowering treatmentUse of insulinRisk of hypoglycemiaOptumLabs Data WarehouseAdults 18 yearsSerious chronic conditionsEligible patientsHbA1c levelsRenal diseaseHbA1c testEmergency departmentChronic conditionsPractice guidelinesRetrospective analysis
2012
The Use and Misuse of Thrombolytic Therapy Within the Veterans Health Administration
Keyhani S, Arling G, Williams LS, Ross JS, Ordin DL, Myers J, Tyndall G, Vogel B, Bravata DM. The Use and Misuse of Thrombolytic Therapy Within the Veterans Health Administration. Medical Care 2012, 50: 66-73. PMID: 22182924, DOI: 10.1097/mlr.0b013e3182294092.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAgedAged, 80 and overBrain IschemiaFemaleFibrinolytic AgentsHealth Services MisuseHealth Status IndicatorsHumansMaleMiddle AgedRetrospective StudiesSocioeconomic FactorsStrokeThrombolytic TherapyTime FactorsTissue Plasminogen ActivatorUnited StatesUnited States Department of Veterans AffairsConceptsVHA medical centersTissue plasminogen activatorVeterans Health AdministrationAcute ischemic strokeEligible patientsStroke patientsIschemic strokeSymptom onsetThrombolytic therapyHealth AdministrationStroke symptom onsetAcute stroke patientsIschemic stroke patientsEligible stroke patientsMedical record reviewLow annual volumeThrombolysis deliveryRecord reviewWrong doseVHA systemClinical conditionsMedical CenterEligible veteransEligibility criteriaPatients
2011
Estimating and Reporting on the Quality of Inpatient Stroke Care by Veterans Health Administration Medical Centers
Arling G, Reeves M, Ross J, Williams LS, Keyhani S, Chumbler N, Phipps MS, Roumie C, Myers LJ, Salanitro AH, Ordin DL, Myers J, Bravata DM. Estimating and Reporting on the Quality of Inpatient Stroke Care by Veterans Health Administration Medical Centers. Circulation Cardiovascular Quality And Outcomes 2011, 5: 44-51. PMID: 22147888, PMCID: PMC3261327, DOI: 10.1161/circoutcomes.111.961474.Peer-Reviewed Original ResearchConceptsVeterans Health Administration medical centersStroke care qualityEligible patientsMedical CenterInpatient stroke care qualityDeep vein thrombosis prophylaxisEvidence-based quality indicatorsCare qualityInpatient stroke carePressure ulcer risk assessmentUlcer risk assessmentStudy patientsThrombosis prophylaxisEarly ambulationIschemic strokeLipid managementRetrospective cohortDysphagia screeningStroke careMedian numberPatientsFiscal year 2007Interfacility variationQuality indicatorsQI rates